Endocrine, Metabolic & Immune Disorders-Drug Targets

(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

Emilio Jirillo  
Universitá degli Studi di Bari
Dipartimento di Clinica Medica
Immunologia e Malattie Infettive
Sezione di Microbiologia e Immunologia
Piazza Giulio Cesare-Policlinico


VIP in Inflammatory Bowel Disease: State of the Art

Author(s): Catalina Abad, Rosa Gomariz, James Waschek, Javier Leceta, Carmen Martinez, Yasmina Juarranz and Alicia Arranz

Affiliation: The Semel Institute and Department of Psychiatry, The David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.


The pathogenesis of inflammatory bowel syndrome (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC) is poorly understood. However, an inflammatory component is a common hallmark. It has been suggested that CD principally involves Th1 and/or Th17 cells, while UC is considered to be more Th2 driven. Because vasoactive intestinal peptide (VIP) has emerged in the last decade as a putative candidate for the treatment of inflammatory diseases with a Th1 component, it may as well serve as a therapeutic target in CD. In addition, experiments using mice deficient in VIP or its receptors have revealed that the endogenously-produced VIP may participate in the regulation of immunity. The aim of the present review is to summarize the quite considerable array of data which suggests that the VIP-receptor system plays a key role in modulating multiple molecular and cellular players involved in IBD.

Keywords: Crohn’s disease, IBD, inflammation, neuroimmunomodulation, neuropeptide, VIP, Autoimmune diseases, ulcerative colitis (UC), predominant anti-inflammatory action, neuroimmunopeptide, pituitary adenylate cyclaseactivating polypeptide (PACAP), airflow obstruction, airway inflammation.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [316 - 322]
Pages: 7
DOI: 10.2174/187153012803832576